Turning Point Therapeutics, Inc.

Tp Therapeutics, Inc.

The University of New Mexico

Sanford-burnham Medical Research Institute

Dayong Zhai

Jingrong Jean Cui

Evan W Rogers

Wei Deng

Jane Ung

Yishan Li

Han Zhang

Jeffrey Whitten

Zhongdong Huang

Jing Liu

Xin Zhang

Brion William Murray

Laura Rodon

Vivian Nguyen

John C Reed

Larry A Sklar

Eric R Prossnitz

Angela Wandinger-Ness

Peter C Simons

Mathewos Z Tessema

Nathan V Lee

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

Diaryl macrocycles as modulators of protein kinases

This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.

Chiral diaryl macrocycles and uses thereof

The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSFR, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Macrocyclic compounds and uses thereof

The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.

Combination therapy involving diaryl macrocyclic compounds

The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.

Macrocycles for use in treating disease

The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.

The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.

Macrocyclic compounds for treating disease

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, of the formula I: pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

Growing community of inventors

San Diego, CA, United States of America

Dayong Zhai